Compare Crispr Therapeutics AG (CRSP) vs DoorDash Inc (DASH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs DoorDash Inc — how do they compare? Crispr Therapeutics AG trades at $53.42 (market cap $4.88B), while DoorDash Inc trades at $196.62 (market cap $83.07B). The key difference: DoorDash Inc is far larger — about 17× Crispr Therapeutics AG's market cap, and DoorDash Inc is more actively traded (3,242,567 versus 2,861,747). Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and DoorDash Inc for 59 Days on average.
| CRSP | DASH | |
|---|---|---|
Market Cap | $4.88B | $83.07B |
Volume | 2,861,747 | 3,242,567 |
Sector | Health | Media |
52-Week High | $74.92 | $275.44 |
52-Week Low | $44.34 | $146.60 |
Typical Hold Time | 77 Days | 59 Days |
Enterprise Value | $3.30B | $81.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
DoorDash (DASH) trades at $196.33, up 2.66% today, with a bullish technical signal from moving averages. The company shows strong revenue growth from $6.6B in 2022 to $13.7B in 2025, achieving profitability with net income of $935M. Recent developments include AI-powered text ordering and drone delivery expansion. Analyst consensus remains strongly bullish with 75% buy ratings and a $255.80 price target, representing 30% upside potential from current levels.
The outlook remains positive with continued revenue growth projected to $15.9B in 2026, though net income may moderate to $841M. Key risks include competitive pressures, regulatory scrutiny from ongoing investigations, and execution challenges in new initiatives. The stock trades at premium valuations (P/E 100.37) requiring sustained growth to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →
